Medico Remedies Ltd Upgraded to Hold as Technicals Improve and Financials Strengthen

Technical Trends Shift to Mildly Bearish

The primary catalyst for the upgrade stems from a notable change in the company’s technical grade. Previously classified as bearish, the technical trend has now shifted to mildly bearish, indicating a less pessimistic market sentiment. Weekly technical indicators show a mildly bullish MACD and KST, alongside bullish Bollinger Bands, suggesting some upward momentum in the short term. However, monthly indicators remain bearish, with the MACD and Bollinger Bands signalling caution over a longer horizon.

Other technical signals present a mixed picture: the Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, while moving averages on a daily basis remain mildly bearish. The On-Balance Volume (OBV) is mildly bearish weekly but neutral monthly, and Dow Theory trends show no definitive direction. This blend of signals has led to a tempered upgrade, reflecting improving but still uncertain technical conditions.

Financial Trend: Positive Quarterly Performance

Medico Remedies has demonstrated encouraging financial results in the latest quarter (Q4 FY25-26), which have supported the rating revision. Net sales surged by 37.55% to ₹56.81 crores, while PBDIT reached a quarterly high of ₹7.15 crores. Profit before tax excluding other income also hit a peak at ₹5.45 crores. These figures mark the fifth consecutive quarter of positive results, underscoring a consistent upward trajectory in operational performance.

The company’s return on capital employed (ROCE) stands at a robust 15.04%, reflecting high management efficiency in deploying capital profitably. Additionally, the debt servicing capability remains strong, with a low Debt to EBITDA ratio of 0.82 times, indicating manageable leverage and financial stability. These factors collectively enhance the company’s financial trend rating, justifying a more favourable outlook.

Valuation: Fair but Discounted Relative to Peers

Despite the positive financial momentum, Medico Remedies’ valuation remains moderate, contributing to the Hold rating rather than a Buy. The company’s ROCE of 15.8% aligns with a fair valuation, supported by an enterprise value to capital employed ratio of 4.8. This suggests that the stock is reasonably priced relative to the capital it employs to generate earnings.

Importantly, the stock trades at a discount compared to its peers’ average historical valuations, offering potential value for investors willing to look beyond short-term price fluctuations. The price-earnings-to-growth (PEG) ratio of 0.9 further indicates that the stock is undervalued relative to its earnings growth, which has risen by 30% over the past year.

However, the stock’s recent price performance has lagged broader market indices. Over the last year, Medico Remedies has delivered a return of -11.12%, underperforming the BSE500’s negative return of -0.83%. This underperformance tempers enthusiasm and supports the Hold stance.

Quality Assessment: Mixed Long-Term Growth and Strong Management

Quality metrics present a mixed picture. On the positive side, management efficiency is high, as evidenced by the strong ROCE and consistent quarterly profitability. The company’s ability to service debt comfortably adds to its creditworthiness and operational resilience.

Conversely, long-term growth has been modest. Net sales have grown at an annual rate of 14.28% over the past five years, which is moderate for the Pharmaceuticals & Biotechnology sector. Additionally, the stock’s cumulative returns over three years have been negative (-52.72%), despite an impressive five-year return of 538.03%, reflecting significant volatility and cyclical challenges.

Majority ownership remains with promoters, which can be a double-edged sword: it ensures stable control but may limit liquidity and broader investor participation. Overall, the quality grade remains steady, supporting a Hold rating rather than an upgrade to Buy.

Stock Price and Market Context

Medico Remedies closed at ₹42.11 on 17 June 2026, marginally down 0.21% from the previous close of ₹42.20. The stock’s 52-week high stands at ₹56.99, while the low is ₹31.00, indicating a wide trading range and volatility. Today’s intraday range was ₹41.59 to ₹43.92, reflecting some buying interest near current levels.

Comparatively, the Sensex has outperformed Medico Remedies over multiple time frames. For instance, the stock’s one-week return was -3.24% against the Sensex’s 3.91%, and year-to-date returns show a decline of -16.71% versus the Sensex’s -9.87%. Over five years, however, Medico Remedies has delivered a remarkable 538.03% return, far exceeding the Sensex’s 46.30%, highlighting its potential for long-term investors despite recent setbacks.

Conclusion: A Cautious Upgrade Reflecting Mixed Signals

The upgrade of Medico Remedies Ltd from Sell to Hold is a reflection of improving technical indicators, solid recent financial performance, and reasonable valuation metrics. However, the company’s long-term growth challenges, recent underperformance relative to the market, and mixed technical signals prevent a more bullish rating at this stage.

Investors should monitor the company’s quarterly results and technical trends closely, as sustained improvements in these areas could warrant a further upgrade. For now, the Hold rating suggests a wait-and-watch approach, balancing the stock’s potential upside against prevailing risks in the Pharmaceuticals & Biotechnology sector.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today